The Pharmacy Times® Ovarian Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to the group of diseases that originates in the ovaries, fallopian tubes, or the peritoneum.
March 22nd 2024
The treatment is indicated for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Rucaparib Shows Efficacy Across Tumors Associated With Different Genetic Alterations
April 11th 2022Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.
Read More
BLA Submitted for Mirvetuximab Soravtansine in Ovarian Cancer
March 30th 2022ImmunoGen, Inc submits Biologics License Application under the accelerated approval pathway for mirvetuximab soravtansine monotherapy for patients with FRα-high platinum-resistant ovarian cancer previously treated with 1 to 3 prior systemic treatments.
Read More
Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.
Watch
Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how oncology pharmacy professionals can effectively address fatalistic beliefs and perceptions of cancer-related information among rural adults.
Watch